Miicro in PET deal with GlaxoSmithKline

Jan 11, 2004

Neuroimaging drug developer Miicro has signed a study services agreement with GlaxoSmithKline (GSK).

Under the agreement, Chicago-based Miicro will conduct PET imaging studies for GSK, assisting in drug development efforts. Work on the first of these studies for GSK is in progress, according to Miicro.

By AuntMinnie.com staff writers
January 12, 2004

There are several conceivable advantages of F-18 FDG PET/CT over conventional imaging. Image A and B showing an example of the distinctive capability of the F-18 FDG PET/CT. A shows a fusion image of F-18 FDG PET/CT and low-dose CT and B an high resolution chest CT of a patient with an Aspergillus infection. The suspected aspergilloma is concealed on the high resolution CT due to the lung fluids and consolidation. Image C and D (fusion image of F-18 FDG PET/CT and low-dose CT and low-dose CT only, respectively) are examples of the ability to image inflammation while no concurrent abnormalities are visualized, in this case prostatitis (red arrows). Image E, a maximized intensity projection of F-18 FDG PET, shows a patient with lung infections and multiple muscle abscesses after MRSA sepsis. This is an illustrative example of a relevant dissemination investigation. Image and caption available for republishing under Creative Commons license (CC BY 4.0 DEED, Attribution 4.0 International) and courtesy of Annals of Intensive Care.

PET/CT reveals new infections in ICU patients

February 21, 2025

(A) Representative maximum-intensity projection and selected PET/CT images (fused, PET and CT only) of patient with metastatic prostate cancer at 1 hour after injection. (B and C) Low uptake of Ga-68 PSMA-R2 in salivary and submandibular glands is also demonstrated. (D) Images show heterogeneous uptake of Ga-68 PSMA-R2 with varying degrees of intensity in multiple spine bone lesions (vertebral sclerotic lesion with intense PSMA-R2 expression at its periphery indicated with red arrow). HU = Houndsfield unit; SUVbw = body-weight SUV. Images and caption courtesy of the Journal of Nuclear Medicine.

PSMA-PET tracer performs well in clinical trial

February 20, 2025

New! Imaging Life Issue 20 now available

January 1, 2025

Pluvicto safe in patients with impaired kidneys

February 13, 2025